Injection volume, overload, and peak distortion posts 31–48
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
On integration: where the baseline is drawn matters more than most people realise. On a clean chromatogram with well-resolved peaks the choice is inconsequential. On a chromatogram with a trailing shoulder or a rising baseline it matters. Differences of one to two percentage points between defensible integrations are ordinary.
Reversed-phase separates on hydrophobicity. A peptide is retained on a non-polar stationary phase and eluted by increasing organic solvent. For peptides the mobile phase almost always contains an ion-pairing acid, typically 0.1% TFA, which suppresses secondary interactions and sharpens peaks.
On post #31 — agreed on the reasoning, with one qualification.
Column chemistry and particle size: smaller particles (1.7 μm) give better resolution and higher efficiency than larger particles (3.5 μm or 5 μm), at the cost of higher back pressure. Newer methods increasingly use smaller particles.
System suitability testing: injections run before and during the sample run to establish whether the instrument, column and method were performing when the sample was analysed. If suitability did not pass, the sample results from that run are uninterpretable.
Two things before anyone answers the substance.
First, the context in the first post is clear and specific. Second, the question is framed so that an answer can actually address it. Both are the norm here and both matter more than they sound.
This is why a purity figure without the underlying chromatogram is weaker evidence than it appears. It is also why two competent laboratories can report different numbers on the same vial without either being wrong.
Method validation is the demonstration that a method can separate the compound from its degradation products and impurities reliably. A method that cannot resolve an impurity from the parent peak will not detect that impurity.
post #39 is right about the mechanism and I think understates the practical bit.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Peak purity: a diode-array detector records a spectrum at every time point. If a peak contains two co-eluting species with different spectra, the spectrum changes across the peak. A passing peak-purity result says the spectrum is constant; it is weak evidence of homogeneity if the impurities have similar spectra.
Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.
The correction was fair and I had been repeating something I had not checked carefully enough.
This follows post #40 rather than contradicting it.
Before anything else: what was the gradient, and at what wavelength? Area percent at different wavelengths is not the same number even on the same sample because different species absorb differently at different wavelengths. With the method stated, I can tell you something useful. Without it, all I can say is that there is one large peak.
I read post #42 twice before replying, because I had assumed the opposite.
Gradient slope is the single biggest driver of apparent purity differences. A shallower gradient over a longer run resolves more impurities and gives a higher purity figure. A steep gradient produces a tidier-looking chromatogram with fewer visible peaks and gives a lower purity figure. Both are legitimate methods and they will not produce the same number.
System suitability testing: injections run before and during the sample run to establish whether the instrument, column and method were performing when the sample was analysed. If suitability did not pass, the sample results from that run are uninterpretable.
Column chemistry and particle size: smaller particles (1.7 μm) give better resolution and higher efficiency than larger particles (3.5 μm or 5 μm), at the cost of higher back pressure. Newer methods increasingly use smaller particles.
Coming back to post #46, because the follow-up matters more than the original answer.
This is why a purity figure without the underlying chromatogram is weaker evidence than it appears. It is also why two competent laboratories can report different numbers on the same vial without either being wrong.
This topic was referenced in
- [2026 update] Why 99.2% and 97.8% on the same lot can both be correctAnalytics › HPLC & UHPLC · 5 replies
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
About the HPLC & UHPLC category
Reversed-phase separations, gradients, columns, integration, and reading a chromatogram properly. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is recorded…
|
4 | 137 | 18h | |
|
Shoulders, tangent skims, and defensible integration
Posting this under the heading it deserves: Shoulders, tangent skims, and defensible integration Everything below is what sits behind that. Posting the method first, because I know what the first three…
|
+16 | 20 | 11k | 13h |
|
[2026 update] Why 99.2% and 97.8% on the same lot can both be correct
Why 99.2% and 97.8% on the same lot can both be correct — that is the question, and I have not found it answered plainly anywhere I have looked. I would like to understand what this number means before I…
|
+1 | 5 | 719 | 2d |
|
Gradient steepness and apparent purity: a worked comparison — the long version
Gradient steepness and apparent purity: a worked comparison — the long version — setting out what I have, and where I think it stops being reliable. A documentation question rather than an analytical one. I…
|
2 | 32k | 1d | |
|
System suitability injections: if they failed, the run did not happen — the long version
System suitability injections: if they failed, the run did not happen — the long version — setting out what I have, and where I think it stops being reliable. A documentation question rather than an…
|
+2 | 6 | 6.2k | 1d |
Related topics — sharing the tags peak integration, system suitability, HPLC
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Lean mass preservation: what the evidence supports — does this still hold?
Asking directly, because I could not find a straight answer: Lean mass preservation: what the evidence supports — does this still hold? Maintenance rather than loss, which is the part of this that almost…
|
+112 | 122 | 5.2k | 20h |
|
Designing a personal experiment that could change your mind — one year on
Designing a personal experiment that could change your mind — one year on — setting out what I have, and where I think it stops being reliable. Session topic: STEP 4 ( JAMA , 2021). Please read it before…
|
+74 | 80 | 17k | 2d |
|
[2026 update] Comparing prices across jurisdictions without misleading yourself
On the subject in the title: Comparing prices across jurisdictions without misleading yourself Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…
|
2 | 809 | 23h | |
|
Whether an aggregate is worth publishing at all: a disputed topic — does this still hold?
Whether an aggregate is worth publishing at all: a disputed topic — does this still hold? I have a specific reason for asking rather than idle curiosity, and the context is below. I would like to understand…
|
+14 | 18 | 3.4k | 2mo |
|
Where the integrator drew the baseline, and how much it moved the number
Where the integrator drew the baseline, and how much it moved the number — setting out what I have, and where I think it stops being reliable. Posting the method first, because I know what the first three…
|
+20 | 24 | 1.6k | 8mo |